3.7300 +0.04 (1.08%)
Pre-Market: 8:14AM EDT
|Bid||0.0000 x 2900|
|Ask||0.0000 x 2900|
|Day's Range||3.3800 - 3.7200|
|52 Week Range||1.8200 - 6.9400|
|Beta (3Y Monthly)||1.99|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 1, 2017 - Nov 6, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.17|
The U.S. Securities and Exchange Commission sued the company for selectively sharing information with analysts that the regulator alleges was not revealed to the public.
CEO of Therapeuticsmd Inc (30-Year Financial, Insider Trades) Robert G Finizio (insider trades) bought 35,000 shares of TXMD on 08/20/2019 at an average price of $2.74 a share. Continue reading...
TherapeuticsMD Inc. shares slid about 6% Tuesday, after the Securities and Exchange Commission charged the company with breaching Regulation FD, or fair disclosure, for sharing material, non-public information with sell-side research analysts that was not disseminated more widely. The SEC found that on two separate occasions in 2017, TherapeuticsMD selectively shared material information with analysts about its interactions with the Food and Drug Administration. In the first instance, the company on June 15, 2017, a day after a meeting with the FDA about a new drug approval, shared private messages with sell-side analysts in which it described the meeting as "very positive and productive." The stock rallied 19.4% in heavy volume the following day, even though the company had not issued a press release or made a public disclosure about the meeting. On July 17 of the same year, the company issued a press release saying it had submitted additional information to the regulator but did not yet have a clear path toward approval. The stock fell 16% premarket. The SEC then found that in a call and email to sell-side analysts, the company shared further details of its initial FDA meeting, which analysts then included in research notes that helped the stock rebound to close the regular session down just 6.6%. "Information about a pharmaceutical company's interactions with the FDA can be critical to investors," said Carolyn Welshhans, associate director of the SEC's division of enforcement. "It is essential that when companies disseminate material, nonpublic information, they do so fairly and appropriately to all investors and not just a select few analysts." TherapeuticsMD consented to the SEC charge and agreed to pay a $200,000 penalty without admitting or denying the findings. The stock has fallen 31% in 2019, while the S&P 500 has gained 16%.
CEO of Therapeuticsmd Inc (30-Year Financial, Insider Trades) Robert G Finizio (insider trades) bought 52,405 shares of TXMD on 08/09/2019 at an average price of $2.96 a share. Continue reading...
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -5.56% and 19.27%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
If you own shares in TherapeuticsMD, Inc. (NASDAQ:TXMD) then it's worth thinking about how it contributes to the...
On CNBC's "Mad Money Lightning Round," Jim Cramer said he likes Yeti Holdings Inc (NYSE: YETI ) very much. He believes the stock is undervalued and he sees it as a long-time hold. Daktronics, ...
TherapeuticsMD Inc NASDAQ/NGS:TXMDView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is high * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is extremely high for TXMD with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting TXMD. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, growth of ETFs holding TXMD is favorable, with net inflows of $2.51 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
TherapeuticsMD (TXMD) grants exclusive commercialization rights to its drugs, Bijuva and Imvexxy, to Theramex in ex-U.S. markets except for Canada and Israel.
TherapeuticsMD, Inc. (TXMD), an innovative, leading women’s healthcare company, will host its Investor and Analyst Day today in New York City. Members of TherapeuticsMD’s management team and key opinion leaders will provide updates on the company’s commercial programs and TherapeuticsMD’s management team will provide financial guidance for 2019. A live webcast and audio archive for the event may be accessed on the home page or from the “Investors & Media” section of the TherapeuticsMD website at www.therapeuticsmd.com.
TherapeuticsMD, Inc. (TXMD), an innovative, leading women’s healthcare company, today announced that it has entered into an exclusive license and supply agreement with Theramex, a leading, global specialty pharmaceutical company dedicated to women’s health, to commercialize BIJUVA (estradiol and progesterone capsules) and IMVEXXY (estradiol vaginal inserts) outside of the United States. Theramex is a portfolio company of CVC Capital Partners.
TherapeuticsMD, Inc. (TXMD), an innovative, leading women’s healthcare company, today announced that it will host an Investor and Analyst Day on Monday, June 10, 2019, in New York City. Members of TherapeuticsMD’s management team and key opinion leaders will provide updates on the company’s commercial programs.
TherapeuticsMD, Inc. (TXMD), an innovative, leading women’s healthcare company, today announced that the company will participate in the Bank of America Merrill Lynch 2019 Health Care Conference. Chief Executive Officer Robert G. Finizio will provide an overview of the company at the conference.